RU2001126301A - CRYSTALLINE MODIFICATION D 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID - Google Patents

CRYSTALLINE MODIFICATION D 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID

Info

Publication number
RU2001126301A
RU2001126301A RU2001126301/04A RU2001126301A RU2001126301A RU 2001126301 A RU2001126301 A RU 2001126301A RU 2001126301/04 A RU2001126301/04 A RU 2001126301/04A RU 2001126301 A RU2001126301 A RU 2001126301A RU 2001126301 A RU2001126301 A RU 2001126301A
Authority
RU
Russia
Prior art keywords
ccdc
modification
nonan
cyan
cyclopropyl
Prior art date
Application number
RU2001126301/04A
Other languages
Russian (ru)
Other versions
RU2248357C2 (en
Inventor
Томас Химмлер
Хуберт Раст
Original Assignee
Байер Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19908448A external-priority patent/DE19908448A1/en
Application filed by Байер Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of RU2001126301A publication Critical patent/RU2001126301A/en
Application granted granted Critical
Publication of RU2248357C2 publication Critical patent/RU2248357C2/en

Links

Claims (7)

1. 8-Циан-1-циклопропил-7-(18,68-2,8-диазабицикло[4.3.0]нонан-8-ил)-6-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновая кислота (CCDC) кристаллической модификации D, отличающаяся тем, что она имеет рентгено-дифрактограмму со следующими рефлексами (2 тэта) с повышенной и средней интенсивностью1. 8-Cyan-1-cyclopropyl-7- (18.68-2.8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid (CCDC) crystalline modification D, characterized in that it has an X-ray diffraction pattern with the following reflexes (2 theta) with high and medium intensity
Figure 00000001
Figure 00000001
2. 8-Циан-1-циклопропил-7-(18,68-2,8-диазабицикло[4.3.0]нонан-8-ил)-б-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновая кислота (CCDC) кристаллической модификации D, отличающаяся тем, что она имеет рентгено-дифрактограмму со следующими рефлексами (2 тэта) с повышенной и средней интенсивностью.2. 8-Cyan-1-cyclopropyl-7- (18.68-2.8-diazabicyclo [4.3.0] nonan-8-yl) -b-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid (CCDC) crystalline modification D, characterized in that it has an X-ray diffraction pattern with the following reflexes (2 theta) with high and medium intensity. и имеет определенную с помощью ДТА среднюю температуру плавления 261-265°С.and has an average melting point of 261-265 ° C. determined by DTA. 3. 8-Циан-1 1-циклопропил-7-(1S,6S-2,8-диазабицикто(4.3.0) нонан-8-ил)6-фтор-1,4-дигидро-4-оксо-3-хинолинкарбоновая кислота (CCDC) кристаллической модификации D, полученная таким образом, что CCDC неизвестной модификации или аморфную CCDC растворяют в воде при концентрации 1-3 вес.%, спустя некоторое время отфильтровывают выпавшее твердое вещество, сушат его и нагревают при температуре, превышающей температуру перехода.3. 8-Cyan-1 1-cyclopropyl-7- (1S, 6S-2,8-diazabicycto (4.3.0) nonan-8-yl) 6-fluoro-1,4-dihydro-4-oxo-3- quinoline carboxylic acid (CCDC) of crystalline modification D, obtained in such a way that CCDC of unknown modification or amorphous CCDC is dissolved in water at a concentration of 1-3 wt.%, after some time the precipitated solid is filtered off, dried and heated at a temperature above the transition temperature . 4. Способ получения CCDC модификации D, отличающийся тем, что CCDC неизвестной модификации или аморфную CCDC растворяют в воде при концентрации 1-3 вес.%, спустя некоторое время отфильтровывают выпавшее твердое вещество, сушат его и нагревают при температуре, превышающей температуру перехода.4. A method for producing CCDC modification D, characterized in that CCDC of unknown modification or amorphous CCDC is dissolved in water at a concentration of 1-3 wt.%, After some time the precipitated solid is filtered off, dried and heated at a temperature above the transition temperature. 5. Лекарственное средство, отличающееся тем, что оно содержит наряду с обычными вспомогательньми веществами и наполнителями CCDC модификации D по одному из пп.1 и 2.5. A medicine, characterized in that it contains, along with the usual excipients and excipients of CCDC, modification D according to one of claims 1 and 2. 6. Применение CCDC модификации D по одному из пп.1 и 2 для получения лекарственных средств.6. The use of CCDC modification D according to one of claims 1 and 2 for the manufacture of medicines. 7. Применение CCDC модификации D по одному из пп.1 и 2 в антибактериальных средствах.7. The use of CCDC modification D according to one of claims 1 and 2 in antibacterial agents.
RU2001126301/04A 1999-02-26 2000-02-14 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo-[4,3,0]-nonane-8-yl)-6- flu oro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of crystalline modification d and medicinal agent eliciting effect against pathogenic microorganisms RU2248357C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19908448A DE19908448A1 (en) 1999-02-26 1999-02-26 Crystal modification D of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo [4.3.0) nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3 -chino incarboxylic acid
DE19908448.3 1999-02-26

Publications (2)

Publication Number Publication Date
RU2001126301A true RU2001126301A (en) 2003-09-20
RU2248357C2 RU2248357C2 (en) 2005-03-20

Family

ID=7899026

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001126301/04A RU2248357C2 (en) 1999-02-26 2000-02-14 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo-[4,3,0]-nonane-8-yl)-6- flu oro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of crystalline modification d and medicinal agent eliciting effect against pathogenic microorganisms

Country Status (22)

Country Link
US (1) US6492391B1 (en)
EP (1) EP1159277A1 (en)
JP (1) JP2002538159A (en)
KR (1) KR100756474B1 (en)
CN (1) CN1217944C (en)
AU (1) AU760710B2 (en)
BR (1) BR0008520A (en)
CA (1) CA2362804A1 (en)
CZ (1) CZ20013065A3 (en)
DE (1) DE19908448A1 (en)
HK (1) HK1045158B (en)
HU (1) HUP0200053A3 (en)
IL (1) IL144528A0 (en)
NO (1) NO320314B1 (en)
NZ (1) NZ513749A (en)
PL (1) PL349394A1 (en)
RU (1) RU2248357C2 (en)
SK (1) SK11942001A3 (en)
TR (1) TR200102435T2 (en)
UA (1) UA71606C2 (en)
WO (1) WO2000052010A1 (en)
ZA (1) ZA200106050B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19854356A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification A of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.0 / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19854355A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification B of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.O / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19908449A1 (en) 1999-02-26 2000-08-31 Bayer Ag Crystal modification C of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo- [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-chino / incarboxylic acid
DE102004015981A1 (en) * 2004-04-01 2005-10-20 Bayer Healthcare Ag New kirstalline form of 8-cyano-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinolinecarboxylic
AU2018217931B2 (en) 2017-02-13 2023-04-13 Elanco Animal Health Gmbh Liquid composition containing pradofloxacin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2676521B2 (en) * 1988-03-22 1997-11-17 北陸製薬株式会社 Method for producing quinolonecarboxylic acid compound type I crystal
MX9703622A (en) * 1994-11-18 1997-08-30 Upjohn Co A new physically stable solid form of a fluoroquinolone.
JP4338217B2 (en) * 1996-02-23 2009-10-07 バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Substitutable 8-cyano-1-cyclopropyl-7- (2,8-diazabicyclo- [4.3.0] -nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo- 3-Quinolinecarboxylic acids and their derivatives
DE19854356A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification A of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.0 / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19854355A1 (en) 1998-11-25 2000-05-31 Bayer Ag Crystal modification B of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicyclo- / 4.3.O / nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-quinoline carboxylic acid
DE19908449A1 (en) 1999-02-26 2000-08-31 Bayer Ag Crystal modification C of 8-cyan-1-cyclopropyl-7- (1S, 6S-2,8-diazabicylo- [4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo 3-chino / incarboxylic acid
JP2001242582A (en) * 2000-02-25 2001-09-07 Fuji Photo Film Co Ltd Silver halide photographic sensitive material and method for processing the same

Similar Documents

Publication Publication Date Title
DK170641B1 (en) Pyrrolidinyl-oxoquinoline carboxylic acid derivatives, process for preparing the same and antimicrobial agent containing the derivatives
DK543787A (en) NAPHTHYRIDINE, QUINOLINE AND BENZOXAZINE CARBOXYLIC ACID COMPOUNDS WITH ANTIBACTERIAL ACTIVITY
DE3750668D1 (en) 7- [3- (Aminomethyl) -3-alkyl-1-pyrrolidinyl] quinoline-3-carboxylic acid derivatives and pharmaceutical compositions containing them.
KR890005199B1 (en) Trifluoro-guinoline-3-carboxylic acids
NO305599B1 (en) New Crystal Forms of Anhydrous 7 - ([1 <alpha>, 5 <alpha>, 6 <alpha>] -6-amino-3-azabicyclo [3.1.0] hex-3-yl) -6-fluoro-1- ( 2,4-difluorophenyl) -1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid methanesulfonic acid salt, process thereof and preparation
DE3880396T2 (en) Kynurenic acid derivatives which can be used for the treatment of neurodegenerative diseases.
RU2001126301A (en) CRYSTALLINE MODIFICATION D 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID
CS51492A3 (en) 2-substituted quinolines, process of their preparation and their use inmedicaments
RU2001117525A (en) CRYSTALLINE MODIFICATION A 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-Fluorine-1, 4-DIHYDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID
AU2005231918B2 (en) Novel crystalline form of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
RU2001117521A (en) CRYSTALLINE MODIFICATION IN 8-CYAN-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-Fluorine-1, 4-DIHYDRO-4-OXO-3 -QINOLINCARBOXYLIC ACID
NO901171L (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED AZETIDINYLPYRIDONCARBOXYLIC ACID DERIVATIVES.
JP2002538159A5 (en)
CA2460970A1 (en) Processes for preparing crystalline and amorphous mupirocin calcium
RU2001126300A (en) CRYSTALLINE MODIFICATION C 8-CYAN-1-CYCLOPROPYL-7 (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUOR-1,4-DIGIDRO-4-OXO-3- Quinoline Carboxylic Acid
KR100756474B1 (en) Crystal modification D of 8-cyano-1-cyclopropyl-7-1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
KR100740947B1 (en) Crystal modification A of 8-cyano-1-cyclopropyl-7-1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
JPH05502229A (en) Imidazo[1,2-a]pyridinyl alkyl compounds for the treatment of neurotoxic injuries
UY23418A1 (en) PROCEDURE FOR THE PREPARATION OF SALTS BY ADDITION OF CRYSTALLINE ESTERS 1- (2,2-DIMETHYLPROPIONYLOXY) -ETHYLIC ACIDS OF DIASTEREOISOMERICALLY PURE 3-CEFEM-4-CARBOXYLIC ACIDS
CA2220080A1 (en) Method for making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form
JPS5925391A (en) Pyridylnaphthyridine derivative and salt thereof
RU2002102491A (en) Quinoline Carboxylic Acid Derivatives Or Their Salts
JPH0348682A (en) Pyridonecarboxylic acid compound
HRP931517A2 (en) Cefalosporin salts and a process for the preparation thereof
EP0221032A2 (en) Sodium salt of etodolic acid and process for its preparation